Search results for "CYTOKINES"

showing 10 items of 845 documents

Cordycepin is an immunoregulatory active ingredient of Cordyceps sinensis.

2008

We have reported that cordycepin, an adenosine derivative from the fungus Cordyceps, increased interleukin (IL)-10 expression, decreased IL-2 expression and suppressed T lymphocyte activity. In the present study, we further characterized the regulatory effects of cordycepin on human immune cells. Moreover, a traditional Chinese drug, Cordyceps sinensis (CS) that contains cordycepin, was also investigated. Cytometric Bead Array (CBA) was used to determine the concentrations of IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, TNF-alpha and IFN-gamma in culture of peripheral blood mononuclear cells (PBMCs). The results showed that both cordycepin and CS up-regulated IL-10, IL-1beta, IL-6,…

AdultMaleT-LymphocytesGene ExpressionBiologyPeripheral blood mononuclear cellchemistry.chemical_compoundImmune systemmedicineHumansTranscription factorCells CulturedCell ProliferationCordycepsCordycepinDeoxyadenosinesPlant ExtractsInterleukinGeneral Medicinebiology.organism_classificationAdenosineComplementary and alternative medicinechemistryBiochemistryCell cultureCordycepsLeukocytes MononuclearCytokinesFemalemedicine.drugProtein BindingTranscription FactorsThe American journal of Chinese medicine
researchProduct

Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.

2015

Intracellular cytokine staining combined with flow cytometry is one of a number of assays designed to assess T-cell immune responses. It has the specific advantage of enabling the simultaneous assessment of multiple phenotypic, differentiation and functional parameters pertaining to responding T-cells, most notably, the expression of multiple effector cytokines. These attributes make the technique particularly suitable for the assessment of T-cell immune responses induced by novel tuberculosis vaccines in clinical trials. However, depending upon the particular nature of a given vaccine and trial setting, there are approaches that may be taken at different stages of the assay that are more s…

AdultMaleT-Lymphocytesmedicine.medical_treatmentlcsh:MedicinePeripheral blood mononuclear cellFlow cytometryAdult; Biomarkers; Cytokines; Female; Flow Cytometry; Humans; Male; T-Lymphocytes; Tuberculosis Vaccines; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Tuberculosis VaccineImmune systemmedicineHumansTuberculosis Vaccineslcsh:ScienceCytokineWhole bloodBiochemistry Genetics and Molecular Biology (all)Multidisciplinarybiologymedicine.diagnostic_testlcsh:RBiomarkerSciences bio-médicales et agricolesFlow Cytometry3. Good healthCytokineT-LymphocyteAgricultural and Biological Sciences (all)Immunologybiology.proteinCytokinesBiomarker (medicine)Femalelcsh:QAntibodyTuberculosis vaccinesBiomarkersHumanResearch ArticlePLoS ONE
researchProduct

Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS‐1)

2007

Thymomas are thymic epithelial neoplasms, associated with a variety of autoimmune disorders (especially myasthenia gravis), that apparently result from aberrant intra-tumourous thymopoiesis and export of inefficiently tolerized T-cells to the periphery. The autoimmune regulator (AIRE) drives the expression of self-antigens in the thymic medulla and plays an essential role in ‘central’ tolerance in both humans and mice. However, while inactivating AIRE mutations result in the ‘autoimmune polyendocrinopathy syndrome type 1’ (APS-1), its major features are not well reproduced in AIRE-knock-out mice. Therefore, alternative human disease scenarios with concomitant AIRE deficiency may be valuable…

AdultMaleThymomaAdolescentThymomaAntibodies NeoplasmThymus Glandmedicine.disease_causeAutoantigensAutoimmune DiseasesPathology and Forensic MedicineAutoimmunity03 medical and health sciences0302 clinical medicineAntigens NeoplasmInterferonMyasthenia GravismedicineHumansPolyendocrinopathies AutoimmuneAgedAutoantibodies030304 developmental biologyAged 80 and over0303 health sciencesbiologybusiness.industryAutoantibodyThymus NeoplasmsMiddle AgedAutoimmune regulatormedicine.diseaseImmunohistochemistryMyasthenia gravisNeoplasm Proteins3. Good healthThymic Tissue030220 oncology & carcinogenesisInterferon Type IImmunologybiology.proteinCytokinesFemaleAntibodybusinessTranscription Factorsmedicine.drugThe Journal of Pathology
researchProduct

Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis

1999

SUMMARYMethotrexate (MTX) is an effective immunosuppressive agent in various chronic inflammatory diseases such as rheumatoid arthritis (RA). However, its mechanisms of action are only partially understood. In this study, we assessed the effects of MTX on the differentiation of peripheral blood (PB) CD4+CD45RA ‘naive’ and CD4+CD45RO ‘memory’ T cells from healthy controls and patients with RA. Accordingly, purified T cells were primed and restimulated in vitro via the T cell receptor (TCR) in the presence of IL-2 to generate effector T cells secreting large amounts of Th1 and Th2 cytokines. We observed that low doses of MTX strongly suppress TNF and to a lesser extent interferon-gamma (IFN-γ…

AdultMaleTime FactorsT-LymphocytesT cellImmunologyReceptors Antigen T-CellPriming (immunology)Enzyme-Linked Immunosorbent AssayMonocytesArthritis RheumatoidInterferon-gammaAntigens CDimmune system diseasesmedicineHumansImmunology and AllergyCytotoxic T cellCells CulturedB-LymphocytesDose-Response Relationship DrugTumor Necrosis Factor-alphabusiness.industryMonocyteSynovial MembraneT-cell receptorCell DifferentiationOriginal ArticlesT lymphocyteMiddle Agedmedicine.diseaseMethotrexatemedicine.anatomical_structureAntirheumatic AgentsRheumatoid arthritisImmunologyCytokinesFemaleTumor necrosis factor alphabusinessClinical and Experimental Immunology
researchProduct

Host immunogenetics and control of human herpesvirus-8 infection

2006

BACKGROUND: Kaposi sarcoma (KS) is primarily caused by human herpesvirus (HHV)-8 infection, and the risk is increased with high HHV-8 lytic or latent antibody titers or the detection of HHV-8 DNA in peripheral blood mononuclear cells (PBMCs). Host genes important for control of HHV-8 infection are not well characterized. METHODS: In 172 HHV-8 latent nuclear antigen (LANA)-seropositive adults in Italy without KS, we examined correlations of common variants in host immune genes with the detection of HHV-8 DNA in PBMCs and with high lytic and latent antibody titers. Twenty-eight single-nucleotide polymorphisms in 14 genes were analyzed. We detected HHV-8 DNA in PBMCs with real-time amplificati…

AdultMaleVascular Endothelial Growth Factor ASimplexvirusfood.ingredientvirusesImmunogeneticsBiologymedicine.disease_causeAntibodies ViralHerpesviridaefoodAntigenLatent Nuclear AntigenRisk FactorsImmunogeneticsmedicineImmunology and AllergyHumansAgedAntibody titervirus diseasesHerpesviridae Infectionsbiochemical phenomena metabolism and nutritionMiddle AgedVirologyEditorial CommentaryTiterInfectious DiseasesLytic cycleHaplotypesImmunologyDNA ViralHerpesvirus 8 HumanLeukocytes MononuclearCytokinesFemale
researchProduct

Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflamma…

2013

Maria D Pinazo-Durán,1,* Carmen Galbis-Estrada,1,* Sheila Pons-Vázquez,1 Jorge Cantú-Dibildox,2 Carla Marco-Ramírez,1 Javier Benítez-del-Castillo21Ophthalmic Research Unit Santiago Grisolia, Department of Surgery/Ophthalmology, Faculty of Medicine, University of Valencia, Valencia, Spain; 2Department of Ophthalmology, Hospital of Jerez, Jerez de la Frontera, Spain*These authors contributed equally to this workBackground: Women, and those older than 65 years of age, are particularly susceptible to dry eye disorders (DEDs). Inflammation is clearly involved in the pathogenesis of DEDs, and there is mounting evidence on the antioxidant and …

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyessential polyunsaturated fatty acidsInterleukin-1betaInflammationnutraceuticsGastroenterologyAntioxidantsPathogenesischemistry.chemical_compoundRisk FactorsInternal medicineFatty Acids Omega-3HumansMedicineProspective StudiesInterleukin 6Prospective cohort studyAgedOriginal ResearchAged 80 and overchemistry.chemical_classificationbiologyInterleukin-6business.industryagingtearsInterleukinGeneral MedicineMiddle AgedcytokinesInterleukin-10Vascular endothelial growth factorchemistryClinical Interventions in AgingDietary SupplementsImmunologybiology.proteinTearsDry Eye SyndromesFemalewomenInflammation MediatorsGeriatrics and Gerontologymedicine.symptombusinessPolyunsaturated fatty acidClinical Interventions in Aging
researchProduct

Serum Irisin Concentrations in Severely Inflamed Patients

2020

AbstractIrisin is a recently discovered exercise-induced myokine that has been attributed the role of favoring white-to-brown adipose tissue trans-differentiation. We confirmed in a population-based cohort that irisin serum concentrations are independently correlated with the habitual level of physical activity, but we also observed an independent correlation with serum concentrations of high-sensitivity C-reactive protein (hs-CRP), thus suggesting that inflammation may influence irisin production. In order to investigate the association between irisin and inflammation, we measured serum irisin concentrations in a group of inflamed inpatients. We hypothesized that if an association between …

AdultMalemedicine.medical_specialtyAdolescentirisin inflammation sepsis fibrinogen cytokines cachexiaEndocrinology Diabetes and MetabolismClinical BiochemistryPopulationAdipose tissue030209 endocrinology & metabolismInflammation030204 cardiovascular system & hematologyFibrinogenSeverity of Illness IndexBiochemistryCachexiaCohort StudiesYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineMyokinemedicineHumanseducationAgedAged 80 and overInflammationCreatinineeducation.field_of_studybusiness.industryBiochemistry (medical)General MedicineMiddle Agedmedicine.diseaseFibronectinsEndocrinologyItalychemistryCase-Control StudiesFemaleTumor necrosis factor alphamedicine.symptombusinessmedicine.drug
researchProduct

Psoriatic arthritis onset in psoriatic patients receiving UV phototherapy in Italy

2018

Abstract BACKGROUND: Psoriasis is a chronic, recurrent, and immune-mediated inflammatory disease that affects 2-3% of the world population. A substantial proportion of patients with psoriasis, approximately 40 %, develop a form of inflammatory arthritis known as psoriatic arthritis (PsA), the arthritis follows the development of psoriasis, and it will develop simultaneously or possibly before the appearance of skin lesions. The presence of PsA indicates a need for more active intervention rather than purely topical therapies or UV-based therapies. The aim of this multicenter, retrospective, epidemiological study was to estimate the incidence of PsA in psoriatic patients receiving UV treatme…

AdultMalemedicine.medical_specialtyAlcohol DrinkingInflammatory arthritisAnti-Inflammatory AgentsArthritisDermatologyComorbidityAsymptomatic030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritis0302 clinical medicineRisk FactorsPsoriasismedicineHumansPsoriasisObesityMetabolic SyndromePast medical historybusiness.industryIncidence (epidemiology)Arthritis PsoriaticSmokingMiddle Agedmedicine.diseaseDermatologyAdipose TissueCardiovascular DiseasesPsoriatic arthritisPopulation studyCytokinesFemaleUltraviolet Therapymedicine.symptomWaist CircumferencebusinessImmunosuppressive Agents
researchProduct

Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid‐resistant acute and chronic graft‐vs‐host disease after allog…

2021

We conducted a multicenter interventional study to assess the efficacy of Therakos ECP to treat steroid-resistant graft-vs-host disease (SRes-GVHD) after allogeneic HSCT and to identify biomarkers of GVHD response. A total of 62 patients were treated for acute SRes-GVHD (n = 37) or chronic SRes-GVHD (n = 25). Median time to best response was 35 days (range, 28-85) and 90 days (range, 27-240) in acute and chronic SRes-GVHD, respectively. Overall, 27 patients (72.9%) with SRes-aGVHD responded to treatment (40.5% CR and 32.4% PR). The response rate was significantly higher in grade I-II than in grade III-IV aGVHD (100% vs 50.0%, respectively, P-value = .001). In chronic SRes-GVHD, 22 patients …

AdultMalemedicine.medical_specialtyCD3Graft vs Host DiseaseDisease030204 cardiovascular system & hematologyT-Lymphocytes RegulatoryGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineExtracorporeal PhotopheresismedicineHumansTransplantation HomologousProspective StudiesIL-2 receptorAgedResponse rate (survey)biologybusiness.industryHematopoietic Stem Cell TransplantationHematopoietic stem cellHematologyGeneral MedicineMiddle AgedTreatment Outcomesurgical procedures operativemedicine.anatomical_structurePhotopheresisbiology.proteinCytokinesBiomarker (medicine)FemaleSteroidsbusinessBiomarkersCD8030215 immunologyJournal of Clinical Apheresis
researchProduct

Anti–Interleukin-12 Antibody for Active Crohn's Disease

2004

Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses.This double-blind trial evaluated the safety and efficacy of a human monoclonal antibody against interleukin-12 (anti-interleukin-12) in 79 patients with active Crohn's disease. Patients were randomly assigned to receive seven weekly subcutaneous injections of 1 mg or 3 mg of anti-interleukin-12 per kilogram of body weight or placebo, with either a four-week interval between the first and second injection (Cohort 1) or no interruption between the two injections (Cohort 2). Safety was the primary end point, an…

AdultMalemedicine.medical_specialtyColonmedicine.medical_treatmentPlaceboGastroenterologychemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodInternal medicinemedicineClinical endpointBriakinumabHumansAgedAged 80 and overCrohn's diseasebiologybusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseInterleukin-12digestive system diseasesCytokinechemistryImmunologyCohortLeukocytes MononuclearInterleukin 12biology.proteinCytokinesFemaleAntibodybusinessNew England Journal of Medicine
researchProduct